Track topics on Twitter Track topics that are important to you
US-based Acura Pharmaceuticals has started developing an immediate-release hydrocodone bitartrate with acetaminophen tablet (hydrocodone/APAP) incorporating its new LIMITX abuse deterrent technology.
Acura Pharmaceuticals Inc., announced today that it is initiating development of an immediate-release hydrocodone bitartrate with acetaminophen tablet ("hydrocodone/APAP") incorporating Acura's novel ...
SAN DIEGO, April 24, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders,...
A survey of pain patients to assess the effects of rescheduling hydrocodone has shown that it negatively…
A study conducted by Stanford researchers led by Christina Smolke developed a technique that can hasten the production of hydrocodone. Hydrocodone and its chemical relatives, such as morphine and oxyc...
Raptor Pharmaceutical has won FDA approval for the expanded use of delayed-release Procysbi, or cysteamine bitartrate, in ped -More-
Cysteamine bitartrate delayed-release capsules were first approved in 2013 for those aged 6 years and older with the rare life-threatening metabolic lysosomal storage disorder nephropathic cystinosis....
OBJECTIVE To evaluate clinical efficacy of hydrocodone-acetaminophen and tramadol for treatment of postoperative pain in dogs undergoing tibial plateau leveling osteotomy (TPLO). ANIMALS 50 client-own...
OBJECTIVE To evaluate the pharmacokinetics of hydrocodone (delivered in combination with acetaminophen) and tramadol in dogs undergoing tibial plateau leveling osteotomy (TPLO). ANIMALS 50 client-owne...
(1) To quantify hydrocodone (HC) and hydromorphone (HM) metabolite pharmacokinetics with pharmacogenetics in CYP2D6 ultra-rapid (UM), extensive (EM) and poor (PM) metabolizer phenotypes. (2) To develo...
An Analysis of Rescue Medication Utilization from a 3-Month, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Low Back Pain Treated with Single-Entity, Twice-Daily, Extended-Release Hydrocodone.
To evaluate the durability of pain relief provided by a new formulation of single-entity, hydrocodone extended-release (ER) (Zohydro(®) ER) throughout the 12-hour dosing interval by examining pattern...
The chemisorption of two chiral molecules, propylene oxide and glycidol, is studied on tartaric-acid modified Pd(111) surfaces by using temperature-programmed desorption to measure adsorbate coverage....